Zobrazeno 1 - 10
of 289
pro vyhledávání: '"crenolanib"'
Autor:
Shanshan Gao, Lingaonan He, Chi Keung Lam, Matthew R. G. Taylor, Luisa Mestroni, Raffaella Lombardi, Suet Nee Chen
Publikováno v:
Cells, Vol 13, Iss 3, p 278 (2024)
Truncating mutations in filamin C (FLNC) are associated with dilated cardiomyopathy and arrhythmogenic cardiomyopathy. FLNC is an actin-binding protein and is known to interact with transmembrane and structural proteins; hence, the ablation of FLNC i
Externí odkaz:
https://doaj.org/article/c2db8f66f7884a4a917fd613fb1c9724
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have a different pathogenesis, clinical characteristics, and treatment respons
Externí odkaz:
https://doaj.org/article/4792834e3de7455bbd0dffc682ef30a2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jia Wang, Ruwen Cui, Cecila G. Clement, Ranjana Nawgiri, Don W. Powell, Irina V. Pinchuk, Tammara L. Watts
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Desmoplasia, a hallmark of a head and neck cancer, has both biologic and physiologic effects on cancer progression and chemotherapeutic response. Mesenchymal stem/stromal cells (MSCs), also known as mesenchymal stromal progenitor cells, have been sho
Externí odkaz:
https://doaj.org/article/92d11a8b70f64a7c93915ceac3a354fd
Autor:
Martin G. Belinsky, Kathy Q. Cai, Yan Zhou, Biao Luo, Jianming Pei, Lori Rink, Margaret von Mehren
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background Most gastrointestinal stromal tumors (GISTs) harbor mutually exclusive gain of function mutations in the receptor tyrosine kinase (RTK) KIT (70–80%) or in the related receptor PDGFRA (~10%). These GISTs generally respond well to
Externí odkaz:
https://doaj.org/article/9eee5c1bb5b142d7958c1fdf045c394f
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e161-e184
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5119cb54cdce7aacfb9028d7ab5d8934
https://doi.org/10.1016/j.clml.2021.09.002
https://doi.org/10.1016/j.clml.2021.09.002
Autor:
Antonio Solana-Altabella, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos
Publikováno v:
EXPERT OPINION ON EMERGING DRUGS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
INTRODUCTION: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with Acute Myeloid Leukemia (AML). Midostaurin, quizartinib, and gilteritinib have been approved in the last years for the treatment of AML, and more Tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77fdcfb29ebeb4d98bc819e1a832e0d
https://doi.org/10.1080/14728214.2021.2009800
https://doi.org/10.1080/14728214.2021.2009800
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sara J. Buhrlage, Xiaoxi Liu, Jing Yang, Jinhua Wang, Abigail E Case, Sophia Adamia, Richard Stone, Chengcheng Meng, Prafulla C. Gokhale, Nathanael S. Gray, Ellen Weisberg, James D. Griffin, Hong L. Tiv, Martin Sattler
Publikováno v:
Journal of Cellular and Molecular Medicine
Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA‐approved FLT3 inhibitor for newly diagnosed patients with FLT3 mutations. However, in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9b94066f50c52e1dc6c57cf1a73e7e
https://doi.org/10.1111/jcmm.14927
https://doi.org/10.1111/jcmm.14927
Autor:
Luke Russell, Sarah A. Steck, Bhuvaneswari Ramaswamy, Daniel G. Stover, Jose Otero, Zaibo Li, Robert Pilarski, Jonathan M. Spehar, Jonathan P. Godbout, Raleigh D. Kladney, Michael C. Ostrowski, Gustavo Leone, Gina M. Sizemore, Steven T. Sizemore, Arnab Chakravarti, Maria C. Cuitiño, Blake E. Hildreth, Christopher Koivisto, Anisha M. Hammer, Lynn Schoenfield, Manjusri Das, Katie A. Thies, Anthony J. Trimboli, Jennifer A. Geisler, Chelsea Bolyard, Matthew D. Ringel, Balveen Kaur, Jerome F. Bey
Publikováno v:
Cancer Research. 81:606-618
Platelet-derived growth factor receptor-beta (PDGFRβ) is a receptor tyrosine kinase found in cells of mesenchymal origin such as fibroblasts and pericytes. Activation of this receptor is dependent on paracrine ligand induction, and its preferred lig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5dd524112bcd03fb8667bb601420a71
https://doi.org/10.1158/0008-5472.can-19-3731
https://doi.org/10.1158/0008-5472.can-19-3731